Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT01605266
Recruiting Observational

INSIGHT (Insight Into Nephrotic Syndrome)

NCT01605266 · tracked via the Priya Life Science Canada tracker
Sponsor
The Hospital for Sick Children
Phase
Observational
Started
2011-01
Last updated
2022-10-25

Condition(s) studied

Nephrotic Syndrome

Study summary

INSIGHT is a longitudinal study of childhood nephrotic syndrome to determine genetic, serologic and environmental factors contributing to nephrotic syndrome and disease progression.

Eligibility

Sex
ALL
Min age
6 Months
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: 1. diagnosis of nephrotic syndrome 2. signed informed consent and assent appropriate for age 3. ages 6 months -18 years old and 4. ability to complete questionnaires Exclusion Criteria: 1. congenital nephrotic syndrome (less than age 1) 2. syndromic disease with multiple organ involvement 3. inability to provide consent by primary care providers 4. conditions such as systemic lupus erythematous.

Primary outcome measure(s)

  • Relapse (number of relapses) — Entire follow-up
    After remission, an increase in the first AM morning urine protein ≥ 3+ for 3 consecutive days or increase in maintenance prednisone dose

Trial sites (4)

FacilityCityRegionStatus
William Osler Health System, Brampton Civic Hospital and Peel Memorial Centre for Integrated Health and Wellness Brampton Ontario Recruiting
Hamilton Health Sciences Corporation - McMaster University Medical Centre Hamilton Ontario Recruiting
Rouge Valley Health System, Rouge Valley Centenary Scarborough Village Ontario Recruiting
The Hospital for Sick Children Toronto Ontario Recruiting

More The Hospital for Sick Children trials in Canada

REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE) Active, not recruiting
Comparison of Ureteral Stent Designs in Children With Kidney Stones Recruiting
Intensive Care Unit Resident Scheduling Trial Recruiting
Adaptive Optics Retinal Imaging in Inherited and Acquired Retinal Disorders Recruiting
CPAP vs High-Flow Nasal Cannula for Treating Sleep Apnea in Children Starting soon

Other trials for the same condition

REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01605266 on ClinicalTrials.gov ↗ ← All trials in Canada